Avanti il prossimo

Riproduzione automatica

Peptide Receptor Radionuclide Therapy (PRRT)

3 Visualizzazioni • 07/09/23
Condividere
Incorporare
administrator
administrator
Iscritti
0

One of the most significant treatment options for neuroendocrine cancer patients became available with the 2018 FDA approval of Lutathera®, the first radiopharmaceutical for Peptide Receptor Radionuclide Therapy (PRRT).

NET experts Dr. Emily Bergsland, Dr. Pamela Kunz, Dr. Erik Mittra and Dr.
Jonathan Strosberg describe the treatment, how it works, and the benefits for patients.

What do physicians look forward to in the future for PRRT?

Mostra di più
0 Commenti sort Ordina per
Commenti su Facebook

Avanti il prossimo

Riproduzione automatica